Loading
Actinium-225 releases four alpha particles as it decays, but the daughters escape and irradiate the kidneys and salivary glands. Nanocarriers try to hold them in place.
The therapeutic power of actinium-225 comes from its decay chain, but recoil energy ejects daughter nuclides from any chelator, causing off-target dose. Nanoparticle carriers (lanthanum phosphate, titanium dioxide, liposomes) and polymer cages are designed to retain daughters long enough for them to decay inside the tumour. Retention above 90% has been reported in animals; no such construct had reached human trials by 2026.
Encapsulating the parent nuclide in a solid-state or multi-shell carrier physically retains recoiling daughters, converting a leaky decay chain into a contained one.
Query for this technology: (TITLE:"Alpha-emitter nanogenerators and daughter trapping" OR ABSTRACT:"Alpha-emitter nanogenerators and daughter trapping") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Alpha-emitter nanogenerators and daughter trapping, not a curated reading list.
Shares Alpha vs beta emitters, Dosimetry, Radical oncology: what could change the war by 2035, Targeted alpha therapy and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.